MT2

10mg / Vial

£20.00

MT2

£20.00

Third-party tested

1–2 day tracked dispatch

Discreet packaging

99%+ purity guaranteed

For Research Use OnlyThis compound is strictly for laboratory and in-vitro research. Not for human consumption or medical use.

Reconstitution

Pen format? Pens are supplied pre-mixed and ready for research use — no reconstitution required. The steps below apply to lyophilized vials only.

Swab both vial stoppers with alcohol and allow to dry.
Draw the required volume of bacteriostatic water with a sterile syringe.
Add the water slowly down the inside wall of the vial — never directly onto the powder.
Swirl gently until fully dissolved. Never shake.
Confirm the solution is clear and particle-free.
Label with date and concentration, then refrigerate at 2–8 °C.

Full guide & dose calculator

Storage & Handling

Lyophilized vials: refrigerate sealed at 2–8 °C away from light; freeze at −20 °C for storage beyond 6 months.
After reconstitution: refrigerate at 2–8 °C; typically stable 4–8 weeks with bacteriostatic water. Do not freeze once mixed.
Pre-mixed pens: arrive ready to use — refrigerate at 2–8 °C with the cap on and never freeze.
General: avoid direct sunlight, heat and repeated temperature swings; minimise agitation.

Quality & Shipping FAQ

Is this compound tested? Yes — every batch is third-party tested by accredited labs (HPLC & mass spectrometry) at 99%+ verified purity.
How is it supplied? As lyophilized powder in a sealed sterile vial (or pre-mixed pen where offered), with research-use labelling.
How fast is dispatch? 1–2 working day dispatch, 2–3 days UK delivery, in plain discreet packaging.
What is it for? Strictly laboratory and in-vitro research — not for human or veterinary consumption, medical use or self-administration.

View the peer-reviewed research

Packaging update Our branded boxes are temporarily out of stock. Until new stock lands, orders ship in plain, discreet packaging — the same product inside, sealed and dispatched with the same care. Thank you for your patience.

Melanotan II (MT2)

Melanotan II is a synthetic cyclic peptide and a non-selective agonist of the melanocortin receptors. It is used as a reference compound in melanocortin-system research.

About the compound

Melanotan II has been studied in published research for its interaction with melanocortin receptors, including MC1R and MC4R. These receptor pathways remain active subjects of laboratory research into melanocortin signalling.

Specifications

Purity: 99%+ (third-party verified)
Independently tested before dispatch
Presented as lyophilised (freeze-dried) powder
Supplied for in-vitro laboratory research only

FAQ

Is it tested? Yes — every batch is independently tested to 99%+ purity before dispatch.
What form does it arrive in? Lyophilised powder.
What is this sold for? Strictly laboratory and research use only. Not for human or animal consumption.

⚖ For Laboratory Research Use Only — Not for Human Consumption.

Melanotan II Skin & Pigmentation Phase I Trial

Phase I Human Trial: Melanotan II Produces Dose-Dependent Skin Tanning in Healthy Volunteers

Life Sciences · Dorr et al., 1996

The first clinical evaluation of MT-II in humans administered escalating doses to Fitzpatrick skin type I/II volunteers. All participants showed significant, objectively measured pigmentation increases within five days, with tanning observed in both sun-exposed and sun-protected areas — confirming a systemic melanogenic effect. This study established a well-tolerated dose range and, through unexpected observations, triggered the research programme that led to FDA-approved bremelanotide.

Phase I Human Trial MC1R Activation Eumelanin Synthesis

Melanocortin (α-MSH) Skin & Pigmentation Human RCT

Afamelanotide for Erythropoietic Protoporphyria

New England Journal of Medicine · Langendonk et al., 2015

Two randomised placebo-controlled trials (168 patients) of afamelanotide, an α-melanocyte-stimulating-hormone (α-MSH) analogue from the same melanocortin family as Melanotan compounds. Subcutaneous implants increased eumelanin-based photoprotection, significantly extending pain-free sunlight exposure and reducing phototoxic reactions, with improved quality of life. Adverse events were mostly mild.

Melanocortin Agonist Melanogenesis Human RCT

Melanotan II Skin & Pigmentation Human Phase 1

Evaluation of Melanotan-II, a Superpotent Cyclic Melanotropic Peptide: Pilot Phase-I Study

Life Sciences · Dorr et al., 1996

A single-blind, placebo-controlled phase-I study in which subcutaneous Melanotan-II, a synthetic α-MSH analogue, produced measurable increases in skin pigmentation — quantified by reflectance spectroscopy — in volunteers after only five low every-other-day doses. The study established that MT-II activates melanocortin receptors to stimulate melanogenesis in humans, with mild transient nausea the principal reported effect.

Melanogenesis Melanocortin Human Phase 1

Melanotan II Skin & Pigmentation In-Vitro

Melanotan II: Melanocortin Receptor Subtype Selectivity and Melanogenesis in Cellular Models

Peptides · Wessells et al., 2003

Melanotan II is a cyclic heptapeptide analogue of alpha-MSH with potent agonist activity at MC1R, MC3R, MC4R, and MC5R. In vitro studies demonstrated significant stimulation of melanogenesis through the cAMP-PKA signalling cascade, producing dose-dependent increases in melanin synthesis in cultured melanocyte models. Its MC4R activity also triggered the research pathway that led to FDA-approved bremelanotide (Vyleesi).

Melanocortin Receptors MC1R cAMP-PKA

View the full research library →